{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:42:02Z","timestamp":1774525322338,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T00:00:00Z","timestamp":1492992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1002\/2327-6924.12458","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T11:42:56Z","timestamp":1493034176000},"page":"294-303","source":"Crossref","is-referenced-by-count":12,"title":["Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma"],"prefix":"10.1097","volume":"29","author":[{"given":"Melissa","family":"Thebeau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyona","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer N.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210303","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD\u20101 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"European Journal of Cancer"},{"key":"R2-10-20210303","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.11.017","article-title":"The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol\u2010Myers Squibb experience","volume":"148","author":"Berman","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"key":"R6-10-20210303","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune\u2010related adverse events and association with outcomes","volume":"22","author":"Freeman\u2010Keller","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"R7-10-20210303","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejca.2016.05.005","article-title":"Diagnosis and treatment of melanoma. European consensus\u2010based interdisciplinary guideline\u2014update 2016","volume":"63","author":"Garbe","year":"2016","journal-title":"European Journal of Cancer"},{"key":"R8-10-20210303","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"R9-10-20210303","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/j.seminoncol.2010.09.015","article-title":"Development of ipilimumab: Contribution to a new paradigm for cancer immunotherapy","volume":"37","author":"Hoos","year":"2010","journal-title":"Seminars in Oncology"},{"key":"R10-10-20210303","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatology"},{"key":"R11-10-20210303","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","article-title":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","volume":"71","author":"Lacouture","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"key":"R12-10-20210303","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"15s","key":"R13-10-20210303","doi-asserted-by":"crossref","first-page":"9506","DOI":"10.1200\/JCO.2016.34.15_suppl.9506","article-title":"Pembrolizumab plus ipilimumab for advanced melanoma: Results of the KEYNOTE029 expansion cohort.","volume":"34","author":"Long","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"R14-10-20210303","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaad.2016.02.1237","article-title":"Gabapentin and pregabalin for the treatment of chronic pruritus","volume":"75","author":"Matsuda","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"key":"R15-10-20210303","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2051","article-title":"Immunostimulatory monoclonal antibodies for cancer therapy","volume":"7","author":"Melero","year":"2007","journal-title":"Nature Reviews in Cancer"},{"key":"R17-10-20210303","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015a","journal-title":"Journal of Clinical Oncology"},{"key":"R18-10-20210303","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015b","journal-title":"New England Journal of Medicine"},{"key":"R19-10-20210303","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator\u2010choice chemotherapy for ipilimumab\u2010refractory melanoma (KEYNOTE\u2010002): A randomized, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncology"},{"key":"R20-10-20210303","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"Journal of the American Medical Association"},{"key":"R21-10-20210303","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015a","journal-title":"New England Journal of Medicine"},{"key":"R22-10-20210303","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015b","journal-title":"New England Journal of Medicine"},{"key":"R23-10-20210303","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatology"},{"key":"R24-10-20210303","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/intimm\/dxw014","article-title":"Mechanisms of tumor escape in the context of the T\u2010cell\u2010inflamed and the non\u2010T\u2010cell\u2010inflamed tumor microenvironment","volume":"28","author":"Spranger","year":"2016","journal-title":"International Immunology"},{"key":"R25-10-20210303","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10555-016-9613-5","article-title":"Genetic progression of malignant melanoma","volume":"35","author":"T\u00edm\u00e1r","year":"2016","journal-title":"Cancer and Metastasis Reviews"},{"key":"R26-10-20210303","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD\u20101\/B7\u2010H1 (PD\u2010L1) pathway to activate anti\u2010tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Current Opinion in Immunology"},{"key":"R28-10-20210303","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune\u2010related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"15s","key":"R29-10-20210303","doi-asserted-by":"crossref","first-page":"9018","DOI":"10.1200\/jco.2015.33.15_suppl.9018","article-title":"Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.","volume":"33","author":"Weber","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"R30-10-20210303","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti\u2010CTLA\u20104 treatment (CheckMate 037): A randomised, controlled, open\u2010label, phase 3 trial","volume":"16","author":"Weber","year":"2015b","journal-title":"Lancet Oncology"}],"container-title":["Journal of the American Association of Nurse Practitioners"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2F2327-6924.12458","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/2327-6924.12458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T16:22:40Z","timestamp":1620922960000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01741002-201705000-00010"}},"subtitle":["A nursing perspective"],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1002\/2327-6924.12458","relation":{},"ISSN":["2327-6924"],"issn-type":[{"value":"2327-6924","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}